Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
EMC$33.86-0.28(-0.82%)EMC Insurance Receives Insurity's Excellence in Operational Efficiency Award[12:01:00 PM ET]SWMR$9.07+0.55(+6.51%)Swarmer to Host Investor Call to Discuss Acquisition of Ratel Robotics[12:00:00 PM ET]CMCSA$22.09-0.61(-2.67%)Comcast Completes Construction in Tulare County, Connecting Thousands to High-Speed Internet for the First Time[12:00:00 PM ET]GCDT$0.14-0.04(-21.86%)Green Circle Decarbonize Technology Limited Issues Statement Regarding Unusual Market Activity[11:45:00 AM ET]KLAR$12.62-0.19(-1.48%)Klarna's flexible payment options now available at Adorama, giving creators more ways to fuel their next project Adorama, a leading photography, video, audio, drone, and computer retailer, and Klarna, the everyday finance network, today announced that Klarna is...[11:39:00 AM ET]DUK$124.55-0.43(-0.34%)Duke Energy Florida shares tips for warding off energy vampires, saving money This Halloween, Duke Energy Florida is reminding customers of the scary reality of energy "vampires" – appliances and electronics lurking throughout...[11:39:00 AM ET]FFR$1.08-0.05(-4.87%)FF EAI Robotics Ecosystem Completed its Acquisition of the Robotics Business of Faraday Future, Establish Nasdaq-Listed Humanoid and Bionic Robotics Platform FF EAI Robotics Ecosystem Inc. ("FFR") (NASDAQ: FFR), a U.S.-based Embodied AI robotics company, and Faraday Future Intelligent Electric Inc....[11:30:00 AM ET]MRK$141.85-3.42(-2.35%)Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer[11:30:00 AM ET]FFR$1.08-0.05(-4.87%)Faraday Future Announces Completion of FF EAI Robotics Ecosystem's (FFR) Acquisition of Faraday Future's Robotics Business and Establishment of a Nasdaq-Listed Humanoid and Bionic Robotics Platform[11:30:00 AM ET]STGW$8.66-0.33(-3.62%)Stagwell (STGW) Acquires Freestar, Leading Publisher Advertising Services Company[11:30:00 AM ET]PGNY$28.40-0.57(-1.97%)New Progyny Study Finds Significant Improvement in Menopause Symptoms Through Connected Care Model[11:25:22 AM ET]

MEDP · NASDAQ

Medpace Holdings, Inc.

$675.26 +6.06 (+0.91%)

Company overview

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a comprehensive suite of services supporting the clinical development process from Phase I to Phase IV across various therapeutic areas. It provides clinical development services to pharmaceutical, biotechnology, and medical device companies, including development plan design, coordinated central laboratory services, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance, new drug application submissions, and post-marketing clinical support. Additionally, Medpace offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Founded in 1992, the company is headquartered in Cincinnati, Ohio.

Sector
Healthcare
Industry
Medical - Diagnostics & Research
Exchange
NASDAQ
Market cap
$18.9B
Employees
5,900
Headquarters
Cincinnati, OH
Website
medpace.com
CEO
August James Troendle
Listed
August 11, 2016
P/E
41.55
Dividend yield
0.00%

Company financials

Revenue
$2.7B
Gross profit
$779M
Operating income
$563M
EBITDA
$580M
Net income
$460M
EPS
$16.24
Total assets
$2.1B
Total debt
$146M
Gross margin
29.07%
Net margin
17.19%
Earnings yield
2.41%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

No geographic segmentation.

Showing FY 2025

Price chart

360.54444.65528.76612.87696.98
MEDP 1D NASDAQ O654.98H670.18L645.93C669.20+15.24 (+2.33%)Vol309.43K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Type
Ticker Type Headline Source Published
MEDPMedpace Holdings, Inc. Stock news Here's Why Medpace (MEDP) is a Strong Growth Stock Zacks Investment Research
MEDPMedpace Holdings, Inc. Legal Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Medpace Holdings, Inc. (MEDP) And Encourages Shareholders to Reach Out ACCESS Newswire
MEDPMedpace Holdings, Inc. Stock news Medpace: Downgrade 'Hold' Revenue Growth Guidance Change And Slightly Lower Backlog Conversion Rate Seeking Alpha
MEDPMedpace Holdings, Inc. Stock news Medpace: 3 Key Takeaways for Long-Term Investors The Motley Fool
MEDPMedpace Holdings, Inc. Legal Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Medpace Holdings, Inc. (MEDP) and Encourages Shareholders to Learn More About the Investigation ACCESS Newswire
MEDPMedpace Holdings, Inc. Stock news Medpace Holdings, Inc. (MEDP) Q3 2026 Earnings Call Transcript Seeking Alpha
MEDPMedpace Holdings, Inc. Stock news Medpace Q3 Earnings Call Highlights MarketBeat
MEDPMedpace Holdings, Inc. Legal Bronstein, Gewirtz & Grossman, LLC Is Investigating Medpace Holdings, Inc. (MEDP) And Encourages Investors to Connect ACCESS Newswire
MEDPMedpace Holdings, Inc. Legal Bronstein, Gewirtz & Grossman, LLC Encourages Medpace Holdings, Inc. (MEDP) Stockholders to Inquire about Securities Investigation ACCESS Newswire
MEDPMedpace Holdings, Inc. Stock news CON vs. MEDP: Which Stock Should Value Investors Buy Now? Zacks Investment Research
MEDPMedpace Holdings, Inc. Stock news Medpace (MEDP) Dips More Than Broader Market: What You Should Know Zacks Investment Research
MEDPMedpace Holdings, Inc. Stock news Medpace: A Shorter, Cleaner Backlog Is Being Mistaken For A Smaller One Seeking Alpha
MEDPMedpace Holdings, Inc. Stock news Medpace (MEDP) Stock Declines While Market Improves: Some Information for Investors Zacks Investment Research
MEDPMedpace Holdings, Inc. Stock news Medpace (MEDP) Rises As Market Takes a Dip: Key Facts Zacks Investment Research
MEDPMedpace Holdings, Inc. Stock news CON or MEDP: Which Is the Better Value Stock Right Now? Zacks Investment Research
MEDPMedpace Holdings, Inc. Stock news Medpace Holdings, Inc. to Report Third Quarter 2026 Financial Results on October 21, 2026 Business Wire
MEDPMedpace Holdings, Inc. Stock news Medpace (MEDP) Outperforms Broader Market: What You Need to Know Zacks Investment Research
MEDPMedpace Holdings, Inc. Stock news Medpace (MEDP) Ascends While Market Falls: Some Facts to Note Zacks Investment Research
MEDPMedpace Holdings, Inc. Stock news CON vs. MEDP: Which Stock Is the Better Value Option? Zacks Investment Research
MEDPMedpace Holdings, Inc. Stock news Why Medpace (MEDP) is a Top Growth Stock for the Long-Term Zacks Investment Research
See more
FAQ

Questions about Medpace Holdings, Inc.

What does Medpace Holdings, Inc. do?
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a comprehensive suite of services supporting the clinical development process from Phase I to Phase IV across various therapeutic areas. It provides clinical development services to pharmaceutical, biotechnology, and medical device companies, including development plan design, coordinated central laboratory services, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance, new drug application submissions, and post-marketing clinical support. Additionally, Medpace offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Founded in 1992, the company is headquartered in Cincinnati, Ohio.
What is MEDP's market cap?
Medpace Holdings, Inc. (MEDP) is a listed stock with a live quote. The latest market cap on this page is $18.9B.
Where is Medpace Holdings, Inc. headquartered?
Medpace Holdings, Inc. is headquartered in Cincinnati, OH.
How do I get MEDP news from the API?
Call GET /v1/news?tickers=MEDP. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does MEDP news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for MEDP, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the MEDP price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. Paid Pro removes the daily cap. If you don't subscribe, the account stays on Free.

Start 7-day free trial Read the docs